Effect of Radioactive Iodine Therapy on Cancer‐Specific Survival of Papillary Thyroid Carcinoma With T4aM0 Stage
Authors' conclusion
RAI therapy does not significantly improve cancer-specific survival in T4aM0 PTC patients after total thyroidectomy.
Study context
- Population
- Papillary thyroid carcinoma (PTC) patients with T4aM0 stage who underwent total thyroidectomy, SEER database
- Participants
- 1,938 patients472 propensity score matching (PSM) pairs
- Exposure
- Radioactive iodine (RAI) therapy vs no RAI after total thyroidectomy
- Outcome
- Cancer-specific survival (CSS)
Methodological detailsSEER database, propensity-score matched, 1:1 nearest-neighbour matching
- SEER database
- Propensity-score matched
- 1:1 nearest-neighbour matching
Main finding
As reported in the abstract
CSS
RAI-treated vs Non-RAI-treatedHazard ratio (95% CI)P value
Entire cohort
0.797(0.540–1.175)
P = 0.252PSM cohort
0.709(0.437–1.151)
P = 0.709Observational data: associations, not effects.
Further findings
Cancer-specific survival (CSS) by subgroup
- No survival benefit of RAI across various clinical characteristics
Original publication
Effect of Radioactive Iodine Therapy on Cancer‐Specific Survival of Papillary Thyroid Carcinoma With T4aM0 Stage. Clin Endocrinol (Oxf). Published 8 March 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →